—
China’s plasma collection was 5,800 tons in 2015. The overall demand needed by the country is predicted to be at 12,000 tons. The blood products market in China is primarily driven by the geriatric populace in need of blood transfusions. Other factors include surgeries involving chronic diseases such as cancer.Browse Full Research Report With TOC on http://www.radiantinsights.com/research/blood-products-markets-in-china
A major factor thwarting progress of the market is the lack of blood centers. Red blood cells have a lifespan of 42 days, while platelets have 5 day lifetime. This factor could also be the panic related to 1980s when one of the blood samples provided was found to be HIV-positive. Since then blood drives are done more cautiously at colleges, healthcare centers, and donations. The market is expected to display growth over the forecast period (2018-2023).
Products encompassed in the market are human albumin, Tetanus immunoglobulin, Human rabies immunoglobulin, Human Immunoglobulin (pH4) for Intravenous Injection, Hepatitis B Immunoglobulin, Human Prothrombin Complex, Blood Coagulation Factor VIII, and human immunoglobulin.
Out of these, human blood coagulation factor VIII sold almost 530,000 bottles in 2013. It has garnered nearly 45% market shares by growing annually. Human albumin had a demand of 14.3 million bottles in the same year. Fibrinogen and human blood coagulation factor VIII grew over 50% on a yearly basis. Government initiatives encouraging market growth are currently involved in constructing blood plasma stations.
Browse All Reports of This Category at: http://www.radiantinsights.com/catalog/healthcare
Prominent vendors in China’s blood products market are Asahi Kasei Medical Co. Ltd., Shanghai RAAS (Rare Antibody Antigen Supply Inc.) Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Beijing Tiantan Biological Products, Ltd.
Mergers & acquisitions are a key strategy adopted by market players to expand their reach. Companies with less than 6 types of blood related products are not allowed to set up plasmapheresis centers. Thus, these companies have resorted to buying stake in smaller startups. For instance, Shanghai RAAS bought Zhengzhou Banghe Pharmaceutical in 2013.
Request A Sample Copy Of This Report at: http://www.radiantinsights.com/research/blood-products-markets-in-china/request-sample
About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Contact Info:
Name: Michelle Thoras
Email: Send Email
Organization: Radiant Insights, Inc.
Address: 28 2nd Street, Suite 3036 San Francisco
Phone: 4153490054
Website: http://www.radiantinsights.com/research/blood-products-markets-in-china
Release ID: 121377
Google
RSS